Arboviral Surveillance and Response Capacity Survey 2021

Section I: Respondent details

1. Country

Bulgaria

- 2. Respondent/person to be contacted for clarification, if needed (last name, first name, e-mail address)
- 3. Professional title and affiliation
- 4. Date (dd/mm/yyyy)

18/5/2021

Section II: Arboviral disease surveillance system

5. Which arboviruses have circulated in your country at any time since the year 2000? This refers only to arboviruses with autochthonous i.e., local mosquitoborne transmission.

| Chikungunya | Not selected |
|--------------|--------------|
| Dengue | Not selected |
| Yellow fever | Not selected |
| Zika | Not selected |
| Other | WNV, CCHF |

6. Do you have any written arbovirus surveillance and control plan(s) and/or guideline(s) for your country?

Yes. We do not have arbovirus-specific guidelines, but arboviruses are included within general surveillance guidelines.

6b. For which of the following arboviruses do you have written surveillance and control plans for your country? Please choose all that apply.

| Chikungunya | Not selected |
|--------------|--------------|
| Dengue | Not selected |
| Yellow fever | Not selected |
| Zika | Not selected |

6c. Please upload surveillance and control plan(s) or protocol(s), or guideline(s)

0 file(s) submitted

7. Is there a specific national programme for arboviral diseases surveillance or is it integrated in another programme? Please select the appropriate answer:

I don't know

7b. Please specify the programme into which arboviral diseases is integrated

8. For which level of the health structure are individual and aggregated data available? (Select all relevant levels)

| | Individual level | Aggregated |
|---------------------------|------------------|--------------|
| Primary health care level | Yes | Not selected |
| District level | Not selected | Not selected |
| Regional level | Not selected | Yes |
| National level | Not selected | Yes |

9. What are the tools used for recording case data for surveillance purposes? Select all that apply

| National | Électronic |
|----------|---------------|
| District | Mixed methods |

10. Which training has been provided to the staff working on arboviral disease surveillance data?

| One-time basic training on data capture and analysis (MS Excel, MS Access, EpiInfo) and/or geographic information systems (GIS) | Not selected |
|---|--------------|
| Repeated/continuing basic training on data capture, analysis, and/or GIS | Not selected |
| One-time advanced training on statistical software for data analysis (e.g. STATA, R, SAS, Tableau, etc.)) and GIS | Not selected |
| Repeated/continuing training on advance statistical software for data analysis (eg STATA, R, SAS, etc) and GIS | Not selected |
| No training | Not selected |

11. Is reporting mandatory for any arboviral disease cases in your country?

Yes

11b. For which of the following arboviral disease cases is reporting mandatory in your country?

| Chikungunya | Mandatory reporting of all suspect cases |
|-----------------------|--|
| Dengue | Mandatory reporting of all suspect cases |
| Yellow fever | Mandatory reporting of all suspect cases |
| Zika (non-congenital) | Mandatory reporting of all suspect cases |
| Zika (congenital) | Mandatory reporting of all suspect cases |
| Other | Mandatory reporting of all suspect cases |

11c. For which other arboviral diseases is reporting mandatory?

| 1 | WNV | All suspect cases |
|---|------|-------------------|
| 2 | CCHF | All suspect cases |

11d. Please upload document(s) containing surveillance case definitions used for reporting of arboviral diseases

0 file(s) submitted

12. In the last 2 years, did your country conduct national epidemiological surveillance for human cases of arboviral disease?

No

- 12b. How frequently are surveillance data reported to the national level?
- 12c. What type of national epidemiological surveillance was conducted?

For reference, here are the relevant definitions:

Active surveillance is defined as having dedicated systems and staff that routinely and with effort survey for cases of disease or detection of vectors and associated pathogens by the public health department.

Passive surveillance is defined as having a reporting system where physicians, laboratories, mosquito control districts, academic institutions or others routinely report cases of disease or detection of vectors and associated pathogens to the public health department.

- 12d. If available, please upload the most recent report(s) on arboviral surveillance in humans
- 13. Does your country provide regular training sessions for healthcare workers on notification of *Aedes*-borne arboviral diseases?

I don't know

14. What do the arboviral disease surveillance staff perceive as factors contributing to the a) success and b) barriers/challenges to arboviral disease surveillance in humans?

Section III: Arbovirus laboratory capacity

15. Is arbovirus diagnostic laboratory testing performed for confirmation of suspected cases in your country? (Please select the applicable option during outbreak periods and during non-outbreak periods, respectively)

| Outbreak periods | All suspect cases tested |
|----------------------|--------------------------|
| Non-outbreak periods | All suspect cases tested |

15b. On average, for what percentage of suspected arboviral disease cases your country is laboratory confirmatory testing performed? Please indicate for outbreak and non-outbreak periods, respectively

Non-outbreak (routine) percentage in a year 70

16. In the last two years, were the positive cases of arboviruses confirmed by a national reference laboratory?

Yes, but only for some arboviral infections. Please specify them:

WNV, CCHF, TBE

16b. If your country does not have capacity to type and serotype arboviruses, do you send samples for typing to other countries?

Yes. Please specify where:

Greece

17. Overall, what arboviral testing capacity(ies) is(are) available in your country? Please check all applicable boxes

| | Antigen testing | IgM antibody testing | IgG antibody testing | Neutralizing Virus antibody isolation testing | RT-PCR or other nucleic acid am- plification test | Viral gene/genome Sequenc- ing |
|--------------|-----------------|----------------------------|----------------------------|---|--|---|
| Chikungunya | | Yes | Yes | | Yes | |
| Dengue | Yes | Yes | Yes | | Yes | |
| Yellow fever | | Yes | Yes | | Yes | |
| Zika | | Yes | Yes | | Yes | |
| Other | | Yes | Yes | | Yes | |

18. Which additional resources are most needed for your country to perform adequate testing for arboviral diseases? Please describe what would be needed for each checked resource in the adjacent comment field

Additional personnel: Yes

Estimate of number of full-time staff: NA

19. Do you perform virological surveillance on humans, ie, tracking of prevailing genotypes/serotypes? Please select all that apply

Yes, using RT-PCR: NA

Yes, using serological testing. Please specify: IFA for DENV

19b. Which samples do you use for virological surveillance?

| Samples from suspected arboviral diseases routinely notified | Yes |
|--|--------------|
| Samples routinely collected from patients with fever of unknown origin | Not selected |

19c. For which viruses do you perform virological surveillance? (check all that apply)

| Chikungunya virus | Yes |
|--------------------|----------------|
| Dengue viruses | Yes |
| Yellow fever virus | Yes |
| Zika virus | Yes |
| Other | WNV, CCHF, TBE |

19d. Does your country provide regular training sessions for healthcare workers on arboviruses virological surveillance?

Yes

20. What do the arboviral diagnostic laboratory staff perceive as factors contributing to the a) success and b) barriers/challenges with respect to laboratory testing for arboviral infections?

Section IV: Management of arboviral disease cases

21. Does your country have clinical guidelines for healthcare workers on diagnosis and clinical management of cases and severe cases of *Aedes*-borne arboviral diseases?

No

21b. Please upload the clinical guideline(s) for arboviral disease management

22. Are severe cases of arboviral diseases managed in a special area (part of the hospital, isolation beds)?

Yes

- 23. How many hospital beds are available per 100,000 population?
- 24. Does your country provide regular training sessions for healthcare workers on clinical diagnosis and management of *Aedes*-borne arboviral diseases?

Yes, specific training is provided. If so, please specify:

NA

25. What do the arboviral disease surveillance/clinical staff perceive as factors contributing to the a) success and b) barriers/challenges with respect to case management?

Section V: Routine vector surveillance and control

26. Is there a disease programme, agency, or service in charge of arbovirus vector surveillance in your country?

No

27. Which institution/department is in charge of reporting entomologic surveillance data to the national ministry of health/health department? (Check all that apply)

| State/provincial health agencies | Yes |
|---|--------------|
| Other national agency | Not selected |
| City/country health departments | Not selected |
| Local mosquito control districts or similar organisations | Not selected |
| Universities or academic institutions | Not selected |
| Private companies | Not selected |

28. For the last 2 years, did your country conduct entomologic surveillance for arboviral infections in mosquito vectors?

No

| 28b. Please upload the most recent national vector surveillance report |
|---|
| 28c. Did the entomologic surveillance entail country wide programmes or was it restricted to specific locations? |
| 28d. How many sentinel surveillance sites do you have? |
| 28e. How often was the surveillance conducted? Please choose one of the following: |
| 29. Do you conduct adult mosquito surveillance? |
| 30. Do you conduct larval/pupal mosquito surveillance? ${\it Yes}$ |
| 31. Are trapped mosquitoes identified to species? Yes |
| 32. Does your country either calculate minimum infection rates (MIR) for any <i>Aedes</i> -borne arboviruses with your mosquito data or receive such data from other agencies? Please choose only one of the following: |

33. Which laboratories performed testing for arboviruses on mosquito pools collected in your country in the last two years? (check all that apply)

No

| National public health laboratory | Yes |
|---|--------------|
| State/provincial/regional public health laboratory | Not selected |
| Local health department laboratory | Not selected |
| University or academic institution | Not selected |
| Local MCD (if different from county health dep't) | Not selected |
| Mosquito surveillance done, but no testing done on mosquito pools | Not selected |
| Not applicable (no mosquito surveillance done) | Not selected |

34. Is there a record of *Aedes aegypti* or *Aedes albopictus* being found in your country in the past 5 years? Please choose only one of the following

Yes, only Aedes albopictus

34b. Please describe the potential public health threat from $Aedes\ aegypti$ in your country

34c. Please describe the potential public health threat from *Aedes albopictus* in your country

 $Aedes\ albopictus$ populations are spreading and pose a significant public health threat

35. Over the past two years, did your country use any of the following vector control methods in local jurisdictions (either using government staff and resources, or subcontracting to a different entity to do so)? Please select all that apply

| Adulticiding (insecticide application against adult mosquitoes) | Yes |
|---|--------------|
| Larviciding | Yes |
| Insect growth regulators (eg , pyriproxyfen) | Yes |
| Wolbachia method | Not selected |
| Sterile insect release | Not selected |
| None | Not selected |

35b. Would your country have conducted or financially supported adulticiding/larviciding or source reduction activities in the last two years if sufficient funding were available?

35c. Which adulticides and/or larvicides (brand and product name) were used?

36. Does your country provide regular training sessions for staff in charge of vector control and vector surveillance?

Yes, only for vector control

37. For the last two years, did your country have a plan for mosquito-borne disease control that includes a threshold (eg, level of vector mosquito abundance or minimum infection rate) that would result in a recommendation for mosquito adulticiding/other mosquito reduction measures?)

No – do not have a formal plan that includes adulticiding to control mosquitoborne diseases

37b. Which indicator(s) is(are) used as threshold(s)?

38. Overall, are data on any of the following arboviral outbreak risk factors routinely collected and analysed? (Select all that apply)

| House Index | Not selected |
|--------------------------------------|--------------|
| Breteau Index | Not selected |
| Container Index | Not selected |
| Temperatures | Not selected |
| Rainfall | Not selected |
| Migration of a non-immune population | Not selected |
| None | Yes |

39. Is there a surveillance system in place for monitoring Aedes resistance to the insecticide(s) used?

No

40. What do the vector surveillance staff perceive as factors contributing to the a) success and b) barriers/challenges with respect to vector surveillance and control in the country?

Section VI: Animal surveillance

41. During the last 2 years, did your country conduct national epidemiological surveillance for arboviral disease in animals (eg, epizootic surveillance for yellow fever in endemic areas)?

I don't know

- 41b. How often was the animal surveillance conducted?
- 41c. What type of surveillance was conducted in animals?
- 41d. Please upload a report on the animal surveillance
- 42. Does your country (or local jurisdictions within the country) perform sentinel animal surveillance or epizootic surveillance, eg, for yellow fever in nonhuman primates in endemic regions?

I don't know

- 42b. For which viruses is sentinel surveillance conducted and in which animal species?
- 42c. Please upload the most recent report(s) on sentinel animal surveillance

Section VII: Community sensitization and participation

43. Does your country have a community outreach program that also covers arboviral diseases?

I don't know

43b. What entity(ies) is(are) in charge of the outreach program in your country?

43c. What is the geographical coverage of the outreach program in your country?

43d. Is the community outreach/social mobilization program sufficiently funded to cover staff time, prevention and outreach activities as needed?

43e. Which resources would help ensure adequate capacity?

44. Did your national arboviral disease program issue notifications to the public about local transmission risk and/or possible vector-control activities (eg larviciding, adulticiding, community mobilization and participation, etc) as a prevention message for arboviral diseases within last 2 years? (Check all that apply)

| | During outbreaks | During non-outbreak periods |
|---|------------------|-----------------------------|
| Issued by national public health agency | Not selected | Not selected |
| Issued by state/local health agencies | Not selected | Not selected |
| No risk in the past two years | Yes | Yes |
| No notifications even though risk was present | Not selected | Not selected |

44b. Which means does your program use for community sensitization, mobilisation and acceptance of interventions in your country? (Check all that apply)

| Press releases to electronic and printed media | Yes |
|---|--------------|
| Public service announcements on television or radio | Yes |
| Passive distribution of informational brochures | Not selected |
| Active distribution of informational brochures | Not selected |
| Town, community, or neighborhood meetings | Not selected |
| Posting information on the home page of your agency's website | Not selected |
| Social media outlets (Facebook, Twitter, etc) | Not selected |
| Door-to-door outreach in selected locations | Not selected |
| Participation in community clean-ups | Not selected |
| Modification of messages for all local languages | Not selected |

45. Does your country provide regular training sessions for staff in charge of community sensitization, mobilisation and acceptance of interventions dedicated to control arboviral diseases?

I don't know

46. What do the community outreach staff perceive as factors contributing to the a) success and b) barriers/challenges with respect to community participation

Section VIII: Preparedness for arboviral outbreaks/epidemics

47. Is there either a surveillance and outbreak response committee in your country, or a steering committee for that purpose?

I don't know

48. Does your country have a contingency plan to organize healthcare services during an outbreak (including outbreaks of arboviral diseases)?

I don't know

- 48b. Please upload the contingency plan
- 49. Are there defined or established criteria for declaring an outbreak of arboviral disease outbreak in your country?

I don't know

- 50. Do you have established collaborations with national/regional research institutions / international agencies that are planned to be activated in case of arboviral outbreak?
- 51. What vector control interventions are deployed in case of an emergency?
- 52. For the last 2 years, which of the following government levels had an emergency fund or a specified emergency funding mechanism for arbovirus outbreak response?

| National level | Yes |
|-------------------|--------------|
| State/local level | Not selected |
| None | Not selected |

53. Does your country provide regular training sessions for staff/committee in charge of preparedness for arboviral outbreaks/epidemics?

Yes

54. What do the arboviral disease surveillance staff perceive as factors contributing to the a) success and b) barriers/challenges with respect to preparedness of arboviral diseases epidemics in your country?

Section IX: Arboviral disease surveillance data

55. Please provide total number of cases and deaths for the following arboviral diseases from 2015 to 2020 (if available).

| | Dengue | Chikungunya | Yellow fever | Zika |
|-------------|--------|-------------|--------------|------|
| 2015 Cases | 0 | 0 | 0 | 0 |
| 2015 Deaths | 0 | 0 | 0 | 0 |
| 2016 Cases | 0 | 0 | 0 | 0 |
| 2016 Deaths | 0 | 0 | 0 | 0 |
| 2017 Cases | 0 | 0 | 0 | 0 |
| 2017 Deaths | 0 | 0 | 0 | 0 |
| 2018 Cases | 0 | 0 | 0 | 0 |
| 2018 Deaths | 0 | 0 | 0 | 0 |
| 2019 Cases | 0 | 0 | 0 | 0 |
| 2019 Deaths | 0 | 0 | 0 | 0 |
| 2020 Cases | 0 | 0 | 0 | 0 |
| 2020 Deaths | 0 | 0 | 0 | 0 |

(NA = Not Available)

55b. Were cases of other mosquito-borne arboviruses, not listed in the previous question, reported in your country from 2015-2020?

Yes

55c. Please select any of the following other mosquito-borne viruses that have been reported in your country from 2015-2020

| West Nile | Yes | |
|-----------|-----|--|
| | | |

55d. Please provide total number of cases and deaths due to each of the following other arboviruses that you selected from 2015-2020

| | West Nile | |
|-------------|-----------|--|
| 2015 Cases | 3 | |
| 2015 Deaths | 0 | |
| 2016 Cases | 2 | |
| 2016 Deaths | 0 | |
| 2017 Cases | 1 | |
| 2017 Deaths | 0 | |
| 2018 Cases | 15 | |
| 2018 Deaths | 3 | |
| 2019 Cases | 8 | |
| 2019 Deaths | 1 | |
| 2020 Cases | 1 | |
| 2020 Deaths | 1 | |

56. Please provide the number of cases of locally acquired, mosquito-borne $\it Aedes$ -borne arbovirus infections by case classification for 2020 and, if not available, for 2019

| | Suspect cases | Probable cases | Confirmed | Deaths |
|--------------|---------------|----------------|-----------|--------|
| | | | cases | |
| Chikungunya | 0 | 0 | 0 | 0 |
| Dengue | 0 | 0 | 0 | 0 |
| Yellow Fever | 0 | 0 | 0 | 0 |
| Zika | 0 | 0 | 0 | 0 |

57. Do arbovirus surveillance staff have any perceived reasons for increasing trends in arboviral disease incidence? Check all answers that apply.

| Climate change (as evidenced by changes in meteorological data) | Not selected |
|---|--------------|
| Construction activities | Not selected |
| Population migration (within the country or between countries) | Not selected |
| Increased availability of peri-domestic water-bearing containers suitable for mosquito egg deposition | Not selected |

Section X: Surveillance staffing

58. During 2019 (prior to the Covid-19 pandemic), indicate below the number of arbovirus surveillance staff at the national level.

| | Number of personnel |
|---|---------------------|
| Epidemiologists | 1 |
| Laboratorians | 2 |
| Entomologists/ vector control specialists | 2 |

59. Indicate below how many total staff persons are needed at the national level in your country to achieve full epidemiology and laboratory capacity* to conduct arbovirus surveillance.

| | Number of personnel |
|--|---------------------|
| Epidemiologists | 2 |
| Laboratorians | 3 |
| Entomologists/vector control specialists | 4 |

60. Optional comments to explain responses to questions 58 and 59 above

Comments for epidemiological staff: Q 58- There is no specially defined staff for arboviral disease surveillance. Latest years the number of epidemiologists at national and regional levels is decreasing and only one epidemiologist (per region) or at national level is responsible for surveillance of all infectious diseases under surveillance in the country. Q 59 - To the moment the number of West Nile fever cases is small and do not put serious surveillance and control management problems so one more epidemiologist as alternate of the one at national level mentioned in the response of Q 58 would be reasonable.

61. The national health authority/ministry of health has access to expertise in clinical management of arboviruses (Check all that apply)

| Within the ministry of health (eg, public health medical officers, clinicians in state hospitals) | Yes |
|---|--------------|
| Through other national agency with regulatory authority | Yes |
| Through academic institution(s) | Not selected |
| Private hospitals | Not selected |
| Does not have access | Not selected |

62. The national health authority/ministry of health has access to expertise in arbovirus epidemiology (Check all that apply)

| Within the ministry of health | Yes |
|---|--------------|
| Through other national agency with regulatory authority | Yes |
| Through academic institution(s) | Not selected |
| Does not have access | Not selected |

63. The national health authority/ministry of health has access to expertise in arbovirus laboratory diagnosis (Check all that apply)

| Within the ministry of health (e.g., public health laboratory scientists) | Yes |
|---|--------------|
| Through other national agency with regulatory authority | Yes |
| Through academic institution(s) | Not selected |
| Does not have access | Not selected |

64. The national health authority/ministry of health has access to expertise in entomology (Check all that apply)

| Within the ministry of health | Yes |
|---|--------------|
| Through other national agency with regulatory authority | Yes |
| Through academic institution(s) | Not selected |
| Does not have access | Not selected |

65. Optional comments to explain responses to any of Questions 61-64

Section XI: Survey conclusion

66. If you have any further comments to add regarding arbovirus surveillance and control in your country, including whether arboviruses other than *Aedes*-borne arboviruses are of higher priority, please do so in the text field below